Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. 2015

Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
Institute of Virology, Technische Universität/Helmholtz Zentrum München, München, Germany; I. Medical Department, Universitätsmedizin, Mainz, Germany; Clinical Registry Unit, I. Medical Department, Universitätsmedizin, Mainz, Germany. Electronic address: martin.sprinzl@unimedizin-mainz.de.

OBJECTIVE Hepatocellular carcinoma (HCC) associated macrophages accelerate tumor progression by growth factor release. Therefore, tumor-associated macrophages (TAM) and their initiated signaling cascades are potential therapeutic targets. Aiming at understanding anticancer effects of systemic HCC therapy, we investigated the impact of sorafenib on macrophage function, focusing on macrophage-related growth factor secretion. METHODS Macrophage markers, cytokine and growth factor release were investigated in CSF-1 (M1) or GMCSF (M2) maturated monocyte-derived macrophages. Macrophages were treated with sorafenib (1.2-5.0 μg/ml) and culture supernatants were transferred to hepatoma cell cultures to assess growth propagation. Insulin-like growth factor (IGF) signaling was blocked with NVP-AEW541 to confirm the role of IGF-1 in macrophage-driven hepatoma cell propagation. Macrophage activation was followed by ELISA of serum soluble mCD163 in sorafenib-treated patients with HCC. RESULTS Alternative macrophages (M2), which showed higher IGF-1 (p=0.022) and CD163 mRNA (p=0.032) expression compared to classical macrophages (M1), increased hepatoma growth. This effect was mediated by M2-conditioned culture media. In turn, sorafenib lowered mCD163 and IGF-1 release by M2 macrophages, which decelerated M2 macrophage driven HuH7 and HepG2 proliferation by 47% and 64%, respectively. IGF-receptor blockage with NVP-AEW541 reduced growth induction by M2-conditioned culture media in a dose dependent manner. A transient mCD163 reduction during sorafenib treatment indicated a coherent M2 macrophage inhibition in patients with HCC. CONCLUSIONS Sorafenib alters macrophage polarization, reduces IGF-1-driven cancer growth in vitro and partially inhibits macrophage activation in vivo. Thus macrophage modulation might contribute to the anti-cancer activity of sorafenib. However, more efficient macrophage-directed therapies are required.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077157 Sorafenib A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate,BAY 43-9006,BAY 545-9085,BAY-545-9085,BAY-673472,Nexavar,Sorafenib N-Oxide,Sorafenib Tosylate,BAY 43 9006,BAY 439006,BAY 545 9085,BAY 5459085,BAY 673472,BAY5459085,Sorafenib N Oxide

Related Publications

Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
May 2007, Archives of toxicology,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
July 1991, Human reproduction (Oxford, England),
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
August 1991, Molecular endocrinology (Baltimore, Md.),
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
March 1991, FEBS letters,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
December 1992, Biochemical and biophysical research communications,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
October 2007, Biochemical and biophysical research communications,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
November 1991, Acta endocrinologica,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
August 2001, The Journal of steroid biochemistry and molecular biology,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
February 1984, The Journal of biological chemistry,
Martin Franz Sprinzl, and Andreas Puschnik, and Anna Melissa Schlitter, and Arno Schad, and Kerstin Ackermann, and Irene Esposito, and Hauke Lang, and Peter Robert Galle, and Arndt Weinmann, and Mathias Heikenwälder, and Ulrike Protzer
May 2008, Annales francaises d'anesthesie et de reanimation,
Copied contents to your clipboard!